＜Research＞Citi Opens 90D Upside Catalyst Watch on LUYE PHARMA (02186.HK)

　　Citi reported that LUYE PHARMA (02186.HK) -0.030 (-1.071%) Short selling $2.38M; Ratio 9.578% has received marketing approval from the US Food and Drug Administration (FDA) for ERZOFRI, an innovative self-developed medication for the treatment of adult patients with schizophrenia, as well as for the treatment of adult patients with schizoaffective disorder as a monotherapy, or as an adjunct to mood stabilisers or antidepressants.

　　Citi said the approval is the first step in the commercialisation of the drug in the US, and the company is seeking to work with local partners to facilitate commercialisation. Considering the potential licensing offer, which is important for the company to reduce debt stress and improve its balance sheet, the broker opened a 90-day upside catalyst watch on the stock.

　　Citi rated LUYE PHARMA Sell with a target price of $2.4.

　　(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2024-07-29 16:25.)

　　AAStocks Financial News